OrganiGram Stock Forecast, Price & News

0.00 (0.00 %)
(As of 06/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume4.60 million shs
Average Volume17.73 million shs
Market Capitalization$906.64 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive OGI News and Ratings via Email

Sign-up to receive the latest news and ratings for OrganiGram and its competitors with MarketBeat's FREE daily newsletter.

OrganiGram logo

About OrganiGram

Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers cannabis flowers, extracts, edibles and oils, beverages, and other cannabis products for adult recreational market under the Edison Reserve, Edison Cannabis Co., ANKR Organics, and Trailblazer brands; and medical cannabis products, including strains, cannabis oils, extracts, edibles, beverages, and vaporizers for the medical market. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.54 out of 5 stars

Medical Sector

518th out of 2,100 stocks

Pharmaceutical Preparations Industry

252nd out of 831 stocks

Analyst Opinion: 4.2Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

OrganiGram (NASDAQ:OGI) Frequently Asked Questions

Is OrganiGram a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OrganiGram stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OGI, but not buy additional shares or sell existing shares.
View analyst ratings for OrganiGram
or view top-rated stocks.

What stocks does MarketBeat like better than OrganiGram?

Wall Street analysts have given OrganiGram a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OrganiGram wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting OrganiGram?

OrganiGram saw a decrease in short interest in the month of May. As of May 28th, there was short interest totaling 11,890,000 shares, a decrease of 13.6% from the May 13th total of 13,760,000 shares. Based on an average daily trading volume, of 11,930,000 shares, the days-to-cover ratio is presently 1.0 days.
View OrganiGram's Short Interest

When is OrganiGram's next earnings date?

OrganiGram is scheduled to release its next quarterly earnings announcement on Tuesday, July 20th 2021.
View our earnings forecast for OrganiGram

How were OrganiGram's earnings last quarter?

OrganiGram Holdings Inc. (NASDAQ:OGI) released its quarterly earnings results on Monday, April, 12th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.26. The firm had revenue of $11.49 million for the quarter, compared to the consensus estimate of $15.70 million. OrganiGram had a negative trailing twelve-month return on equity of 19.11% and a negative net margin of 315.91%.
View OrganiGram's earnings history

How has OrganiGram's stock been impacted by COVID-19 (Coronavirus)?

OrganiGram's stock was trading at $1.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OGI shares have increased by 76.7% and is now trading at $3.04.
View which stocks have been most impacted by COVID-19

What price target have analysts set for OGI?

11 brokers have issued 1-year price objectives for OrganiGram's stock. Their forecasts range from $3.50 to $6.00. On average, they expect OrganiGram's share price to reach $4.47 in the next twelve months. This suggests a possible upside of 47.2% from the stock's current price.
View analysts' price targets for OrganiGram
or view top-rated stocks among Wall Street analysts.

Who are OrganiGram's key executives?

OrganiGram's management team includes the following people:
  • Mr. Gregory Engel, CEO & Director (Age 56, Pay $396.25k)
  • Mr. Derrick W. West CPA, CPA, (CA), Chief Financial Officer (Age 54, Pay $272.13k)
  • Ms. Helen Martin, Sr. VP of Strategic & Legal Affairs and Company Sec. (Age 43, Pay $252.22k)
  • Mr. Paolo De Luca C.A., C.F.A, Chief Strategy Officer (Age 48, Pay $274.01k)
  • Amy Schwalm, VP of Investor Relations
  • Mr. Timothy Emberg, Sr. VP of Sales & Commercial Operations
  • Mr. James Cavanagh, Chief of Staff
  • Mr. Larry Rogers, VP of International Bus. Devel.
  • Mr. Peter R. Hanson, Director of Fin.

Who are some of OrganiGram's key competitors?

What other stocks do shareholders of OrganiGram own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include KushCo (KSHB), (CGC), Auxly Cannabis Group (CBWTF), The Supreme Cannabis (SPRWF), Medical Marijuana (MJNA), Cannabics Pharmaceuticals (CNBX), MariMed (MRMD), Aurora Cannabis (ACB), EVIO (EVIO) and Gran Tierra Energy (GTE).

What is OrganiGram's stock symbol?

OrganiGram trades on the NASDAQ under the ticker symbol "OGI."

Who are OrganiGram's major shareholders?

OrganiGram's stock is owned by many different institutional and retail investors. Top institutional shareholders include Mirae Asset Global Investments Co. Ltd. (1.35%), Millennium Management LLC (1.13%), Penserra Capital Management LLC (0.42%), TD Asset Management Inc. (0.27%), Bank of Montreal Can (0.19%) and Swiss National Bank (0.18%).

Which institutional investors are selling OrganiGram stock?

OGI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Scotia Capital Inc., Sigma Planning Corp, Walleye Capital LLC, and Creative Planning.

Which institutional investors are buying OrganiGram stock?

OGI stock was purchased by a variety of institutional investors in the last quarter, including Mirae Asset Global Investments Co. Ltd., TD Asset Management Inc., Penserra Capital Management LLC, Bank of Montreal Can, Morgan Stanley, HRT Financial LP, Squarepoint Ops LLC, and BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp.

How do I buy shares of OrganiGram?

Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OrganiGram's stock price today?

One share of OGI stock can currently be purchased for approximately $3.04.

How much money does OrganiGram make?

OrganiGram has a market capitalization of $906.64 million and generates $64.61 million in revenue each year. The company earns $-101,290,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis.

How many employees does OrganiGram have?

OrganiGram employs 619 workers across the globe.

What is OrganiGram's official website?

The official website for OrganiGram is

Where are OrganiGram's headquarters?

OrganiGram is headquartered at 35 English Dr., Moncton Z4, E1E 3X3.

How can I contact OrganiGram?

OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at 1-855-961-9420.

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.